Nasdaq keeps Ironwood (NASDAQ: IRWD) listed after bid price recovery

Rhea-AI Filing Summary

Ironwood Pharmaceuticals, Inc. reported that it has regained compliance with the Nasdaq Global Select Market’s minimum bid price requirement. On August 29, 2025, Nasdaq notified the company that its Class A common stock again meets Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share for at least 10 consecutive business days. With this condition satisfied, the prior deficiency notice has been resolved and the matter is now closed, removing the immediate risk of delisting tied to bid price.

Positive

• Nasdaq compliance restored: Ironwood regained compliance with Nasdaq’s $1.00 minimum bid price rule after maintaining the required bid level for 10 consecutive business days, closing out a prior deficiency notice.

Negative

• None.

Insights

Equity Markets Analyst

Ironwood removed an immediate Nasdaq delisting risk by restoring minimum bid compliance.

Nasdaq informed Ironwood Pharmaceuticals on August 29, 2025 that the company once again satisfies the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). This rule mandates a closing bid price of at least $1.00 per share for 10 consecutive business days for continued listing on the Nasdaq Global Select Market.

Ironwood had previously been notified on May 28, 2025 that it was out of compliance because its Class A common stock traded below the $1.00 threshold. The company has now met the 10-day requirement, and Nasdaq considers the matter closed.

This development is positive because it removes a specific listing compliance issue that could have led to delisting if unresolved. Future company disclosures will show whether the share price maintains levels consistent with ongoing compliance under Nasdaq rules.

false 0001446847 0001446847 2025-08-29 2025-08-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to 

Section 13 or 15(d) of the 

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 29, 2025

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-34620		04-3404176
(State or other jurisdiction				(I.R.S. Employer
of incorporation)		(Commission File Number)		Identification Number)

100 Summer Street, Suite 2300
Boston, Massachusetts				02110
(Address of principal
executive offices)				(Zip code)

(617) 621-7722

(Registrant’s telephone number,

including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, $0.001 par value	IRWD	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On August 29, 2025, Ironwood Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”) for continued inclusion on the Nasdaq Global Select Market. As previously disclosed in the Company’s Current Report on Form 8-K filed on June 3, 2025, the Company received a written notice from Nasdaq on May 28, 2025, notifying the Company that it was not in compliance with the Bid Price Rule because its Class A common stock, par value $0.001 per share (the “Common Stock”) had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market. To regain compliance with the Bid Price Rule, the Company’s Common Stock was required to maintain a closing bid price of $1.00 per share or more for at least 10 consecutive business days. This requirement was met, and the matter is now closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Ironwood Pharmaceuticals, Inc.
Dated: September 3, 2025	By:	/s/ Gregory Martini
		Name:	Gregory Martini
		Title:	Senior Vice President, Chief Financial Officer

FAQ

What did Ironwood Pharmaceuticals (IRWD) announce in this 8-K?

Ironwood Pharmaceuticals reported that Nasdaq has notified the company it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.

Why was Ironwood Pharmaceuticals (IRWD) previously out of Nasdaq compliance?

Nasdaq had notified Ironwood on May 28, 2025 that it was not in compliance because its Class A common stock failed to meet the $1.00 per share minimum bid price required by Nasdaq Listing Rule 5450(a)(1).

How did Ironwood regain compliance with Nasdaq’s bid price rule?

To regain compliance, Ironwood’s Class A common stock was required to maintain a closing bid price of $1.00 per share or more for at least 10 consecutive business days, a condition that has now been met.

What does Nasdaq’s confirmation mean for Ironwood’s listing status?

Nasdaq’s letter states that Ironwood again satisfies the minimum bid price requirement, and the bid price deficiency matter is now closed, meaning the company remains listed on the Nasdaq Global Select Market under that rule.

Which Ironwood security is subject to the Nasdaq bid price rule?

The rule applies to Ironwood’s Class A common stock, par value $0.001 per share, which is listed on the Nasdaq Global Select Market under the trading symbol IRWD.

Does this 8-K disclose any new financing or major transaction for Ironwood (IRWD)?

No, the disclosure focuses on Nasdaq confirming Ironwood’s compliance with the minimum bid price listing requirement and does not describe any new financing or major transaction.